NEO.LIFE What to Expect in Neuroscience, Genetics, Longevity, Biotech, and Psychedelics in 2022

Summary: NEO.LIFE reached out to experts in innovative scientific fields, including representatives from MAPS, with a question: “What is the most exciting, impactful, or scary development you’re anticipating in 2022 in your field?”

MAPS Global Impact Officer Natalie Lyla Ginsberg, M.S.W., forecasts significant drug policy changes, increased access to ketamine-assisted therapy, and progress in expanding unique applications of psychedelics, such as “conflict resolution and dialogue work” and “healing climate- and eco-grief.”

“But what is going to move the needle on psychedelics this year will be clinical trial results,” writes author Jane Metcalfe. Berra Yazar-Klosinski, Ph.D., Chief Scientific Officer of MAPS Public Benefit Corporation (MAPS PBC), looks forward to completing enrollment for MAPS’ second Phase 3 clinical trial of MDMA-assisted therapy for PTSD and initiating enrollment in our Phase 2 clinical trail of cannabis for PTSD.

Originally appearing here (Archived)